Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
Completed · Phase 2
Conditions studied: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with paclitaxel and cisplatin works in treating patients with advanced transitional cell cancer of the urothelium.
Key facts
- Study ID
- NCT00310011
- Run by
- Wake Forest University Health Sciences
- People needed
- 71
- Starts
- 1998-06-01
- Expected to finish
- 2009-08-01
- Last updated by the study team
- 2018-08-10
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Carolinas Hematology-Oncology Associates — Charlotte, North Carolina, United States
- Regional Cancer Center — Greensboro, North Carolina, United States
- Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.